Back to Search
Start Over
The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotentDrosophilahematopoietic progenitor cells
- Source :
- Oncotarget, Oncotarget, Impact journals, 2016, 7 (34), pp.55313-55327. ⟨10.18632/oncotarget.10879⟩, Oncotarget, 2016, 7 (34), pp.55313-55327. ⟨10.18632/oncotarget.10879⟩
- Publication Year :
- 2016
- Publisher :
- Impact Journals, LLC, 2016.
-
Abstract
- // Giorgia Giordani 1, 5, * , Marilena Barraco 1, 6, * , Angela Giangrande 2 , Giovanni Martinelli 3 , Viviana Guadagnuolo 3 , Giorgia Simonetti 3 , Giovanni Perini 1, 4 , Roberto Bernardoni 1, 4 1 Department of Pharmacy and Biotechnology (FaBiT), University of Bologna, Bologna, Italy 2 Institut de Genetique et de Biologie Moleculaire et Cellulaire, CNRS/INSERM/ULP 67404 Illkirch, France 3 Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology "L. e A. Seragnoli", University of Bologna, Bologna, Italy 4 Health Sciences and Technology - Interdepartmental Center for Industrial Research (HST-ICIR), University of Bologna, Ozzano Emilia, Italy 5 Present address: Department of Biological Sciences, School of Applied Sciences, University of Huddersfield, Queensgate, Huddersfield, UK 6 Present address: Institute of Hematology, “L e A Seragnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy * These authors contributed equally to this work Correspondence to: Roberto Bernardoni, email: roberto.bernardoni@unibo.it Giovanni Perini, email: giovanni.perini@unibo.it Keywords: PF-04449913, Smoothened inhibitor, leukemia, Drosophila, prohemocytes Received: December 09, 2015 Accepted: June 26, 2016 Published: July 28, 2016 ABSTRACT The efficient treatment of hematological malignancies as Acute Myeloid Leukemia, myelofibrosis and Chronic Myeloid Leukemia, requires the elimination of cancer-initiating cells and the prevention of disease relapse through targeting pathways that stimulate generation and maintenance of these cells. In mammals, inhibition of Smoothened, the key mediator of the Hedgehog signaling pathway, reduces Chronic Myeloid Leukemia progression and propagation. These findings make Smo a candidate target to inhibit maintenance of leukemia-initiating cells. In Drosophila melanogaster the same pathway maintains the hematopoietic precursor cells of the lymph gland, the hematopoietic organ that develops in the larva. Using Drosophila as an in vivo model, we investigated the mode of action of PF-04449913, a small-molecule inhibitor of the human Smo protein. Drosophila larvae fed with PF-04449913 showed traits of altered hematopoietic homeostasis. These include the development of melanotic nodules, increase of circulating hemocytes, the size increase of the lymph gland and accelerated differentiation of blood cells likely due to the exit of multi-potent precursors from quiescence. Importantly, the Smo inhibition can lead to the complete loss of hematopoietic precursors. We conclude that PF-04449913 inhibits Drosophila Smo blocking the Hh signaling pathway and causing the loss of hematopoietic precursor cells. Interestingly, this is the effect expected in patients treated with PF-04449913: number decrease of cancer initiating cells in the bone marrow to reduce the risk of leukemia relapse. Altogether our results indicate that Drosophila comprises a model system for the in vivo study of molecules that target evolutionary conserved pathways implicated in human hematological malignancies.
- Subjects :
- Smoothened inhibitor
0301 basic medicine
medicine.medical_specialty
Prohemocyte
[SDV]Life Sciences [q-bio]
Cellular differentiation
Biology
03 medical and health sciences
prohemocytes
0302 clinical medicine
Internal medicine
medicine
Animals
Homeostasis
Humans
Hematology
Multipotent Stem Cells
Phenylurea Compounds
leukemia
Myeloid leukemia
Cell Differentiation
[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology
medicine.disease
Smoothened Receptor
PF-04449913
Hedgehog signaling pathway
3. Good health
[SDV] Life Sciences [q-bio]
Leukemia
Haematopoiesis
Drosophila melanogaster
030104 developmental biology
medicine.anatomical_structure
Oncology
030220 oncology & carcinogenesis
Immunology
Cancer research
Benzimidazoles
Drosophila
Bone marrow
Smoothened
Research Paper
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....4c7d6bfdf9a1fc89763fb1c1b25afc4d